Prothena (0Y3M) AI Stock Analysis

Prothena

(LSE:0Y3M)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverage and capitalizationVery low leverage and a sizable equity base provide financial flexibility for a clinical-stage biotech whose programs require sustained investment. This capitalization reduces reliance on debt financing and gives Prothena greater capacity to advance its pipeline while managing development uncertainty.

Negative Factors

Declining revenue and deep lossesDeclining revenue alongside deeply negative net and operating margins shows that current collaboration economics are not covering Prothena's development and operating base. Persistent losses can erode equity over time and make future financial performance highly dependent on successful pipeline events.

Prothena (0Y3M) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $434.82M
Dividend Yield: ―
Average Volume (3M): 909
Price to Earnings (P/E): -10.2
Beta (1Y): 0.16
Revenue Growth: 427.32%
EPS Growth: 85.31%
Country: UK
Employees: 67
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Prothena Business Overview & Revenue Model

Company Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...

Prothena Earnings Call Summary

Earnings Call Date:Feb 18, 2026(Q4-2025)|% Change Since:-6.05%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.

Positive Updates

Two Partner Programs Advanced to Phase III

Roche advanced prasinezumab into the Phase III PARAISO trial (≈900 participants; primary completion expected in 2029). Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial (≈1,280 patients; primary completion expected in 2029).

Negative Updates

ARIA‑E and Safety Profile Concerns for PRX012

PRX012 ASCENT reported ARIA‑E rates described as 'noncompetitive' relative to FDA‑approved anti‑Aβ antibodies, prompting a strategic pivot to a PRX012‑transferrin receptor (TfR) program to try to improve the ARIA profile.

Company Guidance

Prothena's 2026 guidance calls for full‑year net cash used in operating and investing activities of $50–55 million, an estimated net loss of $67–72 million (which includes about $24 million of noncash share‑based compensation), and an expected year‑end cash, cash equivalents and restricted cash balance of approximately $255 million at the midpoint; this guidance does not include up to $105 million of potential aggregate clinical milestone payments from partners in 2026. For context, Prothena closed 2025 with $308.4 million in cash (as of Dec 31, 2025), reported 2025 net cash used in operating and investing activities of $163.7 million (favorable to prior guidance of $170–178 million), a 2025 net loss of $244.1 million (in line with guidance of $240–248 million), had 53.8 million ordinary shares outstanding as of Feb 12, 2026, and a simple capital structure with zero debt.

Prothena Risk Analysis

Prothena disclosed 62 risk factors in its most recent earnings report. Prothena reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Prothena Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0Y3M against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVXL	49Neutral	$110.31M	-4.55	-21.11%	―	―	73.28%
IKT	46Neutral	$216.28M	-3.26	-42.80%	―	―	59.89%
ACIU	45Neutral	$225.94M	-4.25	-99.17%	―	-33.68%	4.48%
ALEC	45Neutral	$327.65M	-2.01	-531.04%	―	-82.91%	6.27%
ABOS	43Neutral	$15.20M	-0.14	-166.49%	―	―	29.92%

* Healthcare Sector Average

Performance Comparison

GB:0Y3M and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0Y3M	Prothena Corporation	8.51	-2.36	-21.73%
AVXL	Anavex Life Sciences	1.19	-6.55	-84.63%
ACIU	AC Immune	2.22	-0.96	-30.19%
ALEC	Alector	2.21	0.77	53.47%
IKT	Inhibikase Therapeutics, Inc.	1.55	-0.05	-3.13%
ABOS	Acumen Pharmaceuticals, Inc.	0.21	-1.97	-90.37%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Prothena AI Stock Analysis